Retention Agreements in the Health Care Equipment & Supplies Industry

78 Contracts & Agreements

Browse by Company

Recent Contracts

Retention Agreement, dated August 19, 2024, by and between the Company and Rebecca Markovich, Interim Chief Financial Officer (Talis Biomedical Corp, Filed With SEC on August 19, 2024)
Retention Agreement, dated August 19, 2024, by and between the Company and Robert Kelley, Chief Executive Officer (Talis Biomedical Corp, Filed With SEC on August 19, 2024)
Retention Agreement, dated April 10, 2024, by and between the Company and Rebecca Markovich, Interim Chief Financial Officer (Talis Biomedical Corp, Filed With SEC on August 19, 2024)
Retention Agreement, dated April 10, 2024, by and between the Company and Rebecca Markovich, Interim Chief Financial Officer (Talis Biomedical Corp, Filed With SEC on May 8, 2024)
Retention Agreement, dated as of April 4, 2024, between Shockwave Medical, Inc. and Isaac Zacharias (ShockWave Medical, Inc., Filed With SEC on April 9, 2024)
Form of Retention Payment Agreement (Cue Health Inc., Filed With SEC on March 13, 2024)
Retention Agreement, dated November 13, 2023, by and between the Company and Rebecca Markovich, Interim Chief Financial Officer (Talis Biomedical Corp, Filed With SEC on November 14, 2023)
Retention Agreement, dated October 30, 2023, between Chris Lesovitz and STRATA Skin Sciences, Inc (STRATA Skin Sciences, Inc., Filed With SEC on October 30, 2023)
Bioventus Inc. 2023 Retention Equity Award Plan (Bioventus Inc., Filed With SEC on June 9, 2023)
Retention Agreement, dated March 5, 2021, by and between the Company and Patricia Lang (Colfax CORP, Filed With SEC on March 1, 2023)
Manufacturing Services and Line Retention Agreement between Insulet Corporation and Flex Medical Sales and Marketing, Ltd., dated July 29, 2022 (INSULET CORP, Filed With SEC on February 24, 2023)
Form of Executive Committee Retention Program Letter Agreement (Bausch & Lomb Corp, Filed With SEC on November 2, 2022)
Retention Agreement, dated as of October 31, 2022, between ABIOMED, Inc. and Andrew Greenfield (ABIOMED Inc, Filed With SEC on November 1, 2022)
Retention Package Letter by and between Registrant and Brandy Green, dated April 27, 2022 (ACCURAY INC, Filed With SEC on August 17, 2022)
Retention and Transition Agreement, dated as of June 14, 2022, by and between the Company and Michelle L. Basil (Haemonetics, Filed With SEC on August 10, 2022)
Retention Agreement, dated as of April 17, 2022, by and among Natus Medical Incorporated, Prince Parent Inc. and Thomas J. Sullivan (Natus Medical Incorporated, Filed With SEC on April 18, 2022)
CFO Retention and Transition Agreement, dated as of November 8, 2021, by and between the Company and William P. Burke (Haemonetics, Filed With SEC on February 8, 2022)
Amendment to Amended and Restated Retention Agreement, dated as of January 18, 2021, by and between Obalon Therapeutics, Inc. and Nooshin Hussainy (OBALON THERAPEUTICS INC, Filed With SEC on March 12, 2021)
Amendment and Restated Retention Agreement, dated as of January 18, 2021, by and between Obalon Therapeutics, Inc. and Andrew Rasdal (OBALON THERAPEUTICS INC, Filed With SEC on March 12, 2021)
Retention Agreement, dated March 5, 2021, by and between Colfax Corporation and Brady Shirley (Colfax CORP, Filed With SEC on March 5, 2021)
Retention Agreement, dated March 5, 2021, by and between Colfax Corporation and Shyam Kambeyanda (Colfax CORP, Filed With SEC on March 5, 2021)
Retention Agreement, dated March 5, 2021, by and between Colfax Corporation and Daniel Pryor (Colfax CORP, Filed With SEC on March 5, 2021)
Retention Agreement, dated March 5, 2021, by and between Colfax Corporation and Christopher Hix (Colfax CORP, Filed With SEC on March 5, 2021)
Retention Agreement, dated March 5, 2021, by and between Colfax Corporation and Matthew Trerotola (Colfax CORP, Filed With SEC on March 5, 2021)
Amended and Restated Retention Agreement, dated as of June 9, 2020, by and between Obalon Therapeutics, Inc. and Nooshin Hussainy (OBALON THERAPEUTICS INC, Filed With SEC on June 19, 2020)
Amended and Restated Retention Agreement, dated as of June 9, 2020, by and between Obalon Therapeutics, Inc. and Andrew Rasdal (OBALON THERAPEUTICS INC, Filed With SEC on June 19, 2020)
Amendment to Executive Retention Agreement, by and between TransMedics, Inc. and Stephen Gordon, dated April 10, 2020 (TransMedics Group, Inc., Filed With SEC on April 13, 2020)
Form of Neon Executive Retention Package Letter (Neon Therapeutics, Inc., Filed With SEC on March 2, 2020)
Retention Agreement between the Company and Thomas Soloway, dated November 30, 2019 (Audentes Therapeutics, Inc., Filed With SEC on December 3, 2019)
Retention Agreement between the Company and Natalie Holles, dated November 30, 2019 (Audentes Therapeutics, Inc., Filed With SEC on December 3, 2019)
Retention Agreement between the Company and Matthew Patterson, dated November 30, 2019 (Audentes Therapeutics, Inc., Filed With SEC on December 3, 2019)
Form of Retention Reward Agreement for Executive Officers (TRANSENTERIX INC., Filed With SEC on November 12, 2019)
Executive Retention Agreement, dated as of March 23, 2015, by and among the Registrant and Stephen Gordon (TransMedics Group, Inc., Filed With SEC on April 5, 2019)
Executive Retention Agreement, dated as of November 15, 2007, by and among the Registrant and Tamer I. Khayal, M.D (TransMedics Group, Inc., Filed With SEC on April 5, 2019)
Executive Retention Agreement, dated as of November 15, 2007, by and among the Registrant and Waleed H. Hassanein, M.D (TransMedics Group, Inc., Filed With SEC on April 5, 2019)
Transition and Retention Agreement between Stryker Corporation and Michael D. Hutchinson (Stryker Corp., Filed With SEC on March 27, 2019)
Retention Agreement, dated July 20, 2018, by and between the Registrant and Charles Nicolette (ARGOS THERAPEUTICS INC, Filed With SEC on November 19, 2018)
Retention Agreement, dated July 20, 2018, by and between the Registrant and Richard Katz (ARGOS THERAPEUTICS INC, Filed With SEC on November 19, 2018)
Retention Agreement, dated July 20, 2018, by and between the Registrant and Jeffrey D. Abbey (ARGOS THERAPEUTICS INC, Filed With SEC on November 19, 2018)
Form of Executive Retention Agreement (Non-CEO) (April 2018) (OBALON THERAPEUTICS INC, Filed With SEC on May 10, 2018)